MedTrace Logo

Deescalating Carbapenems in Hospital Setting

NCT02265445 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-02-23

No results posted yet for this study

Summary

The study aims to evaluate a deescalating therapeutic strategy (switch the carbapenem to another beta-lactam for which the isolated pathogen is susceptible) in patients with well-defined ESBL-PE infections (usual sites of infections and non severe infections).

Conditions

  • Urinary Infection
  • Digestive Infection
  • Biliary Infection
  • Expanded-spectrum Beta-lactamase Producing ESBL

Interventions

DRUG

Deescalation therapy

Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.

DRUG

Maintaining carbapenem therapy

Intravenous therapy, Maintaining carbapenem therapy

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Phillipe LESPRIT, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265445 on ClinicalTrials.gov